Stock of Lantern Pharma Inc. (LTRN) is moving down about 10 percent on Friday morning trading after the company, along with its subsidiary Starlight Therapeutics, announced that the U.S. Food and Drug Administration has cleared the Investigational New Drug application for STAR-001 in a planned Phase 1 pediatric clinical trial.
The company's stock is currently trading at $1.88, down 10.04 percent, over the previous close of $2.09 on the Nasdaq. It has traded between $1.82 and $5.7440 in the past one year.
The planned trial will evaluate STAR-001 as a single agent and in combination with spironolactone in pediatric patients with relapsed or refractory central nervous system malignancies.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.